Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. POAI
stocks logo

POAI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Predictive Oncology Inc (POAI.O) is -4.29, compared to its 5-year average forward P/E of -3.81. For a more detailed relative valuation and DCF analysis to assess Predictive Oncology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.81
Current PE
-4.29
Overvalued PE
-0.38
Undervalued PE
-7.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.26
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.41
Undervalued EV/EBITDA
-3.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.17
Current PS
0.00
Overvalued PS
18.18
Undervalued PS
-1.83
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

POAI News & Events

Events Timeline

(ET)
2025-10-14
08:08:04
Predictive Oncology Reveals New Appointments to Leadership Team and Board
select
2025-09-29 (ET)
2025-09-29
09:21:55
Predictive Oncology Sets Pricing for Private Placements to Launch Digital Asset Treasury
select
2025-09-25 (ET)
2025-09-25
08:12:08
Predictive Oncology Declares 1-for-15 Reverse Stock Split
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
09-29Benzinga
Nasdaq Soars 150 Points as US Pending Home Sales Increase
  • U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining approximately 150 points, while the Dow and S&P 500 also saw increases of 0.19% and 0.42%, respectively. Information technology shares rose by 0.8%, while energy stocks fell by 0.8%.

  • Pending Home Sales Surge: U.S. pending home sales increased by 4% in August, marking the largest gain in five months, contrasting with a 0.4% decline in the previous month.

  • Notable Stock Movements: Maison Solutions Inc. shares surged by 257%, while Predictive Oncology Inc. rose by 112% following a reverse stock split. Conversely, KALA Bio, MoonLake Immunotherapeutics, and IO Biotech saw significant declines of 92%, 89%, and 75%, respectively.

  • Global Market Overview: European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.2%. Asian markets closed mixed, with Japan's Nikkei 225 down 0.69% and Hong Kong's Hang Seng up 1.89%.

[object Object]
Preview
8.5
09-29SeekingAlpha
Predictive Oncology Reveals $344 Million in Private Placements
  • Private Placement Transactions: Predictive Oncology announced two private placement transactions to raise approximately $344.4 million, involving the sale of common stock and pre-funded warrants for Aethir tokens.

  • Use of Proceeds: The funds will support the company's digital asset treasury strategy, including acquiring ATH tokens and covering working capital and corporate expenses, with the PIPEs expected to close around October 2, 2025.

[object Object]
Preview
2.0
09-28TipRanks
Stock Splits Scheduled for This Week (September 29 to October 3) – Keep Your Investments Active
  • Upcoming Stock Splits: The week of September 29 to October 3 will see several companies implementing stock splits, including Leslie’s, Cemtrex, Lunai Bioworks, Erayak Power Solution Group, Predictive Oncology, and American Rebel Holdings, primarily as a strategy to comply with Nasdaq's minimum bid price requirements.

  • Types of Stock Splits: Companies are utilizing reverse stock splits to reduce share counts and increase share prices, which helps maintain compliance with exchange listing rules and can enhance investor perception, while traditional stock splits aim to make shares more accessible to retail investors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Predictive Oncology Inc (POAI) stock price today?

The current price of POAI is 5.475 USD — it has decreased -0.64 % in the last trading day.

arrow icon

What is Predictive Oncology Inc (POAI)'s business?

Predictive Oncology Inc. is engaged in using artificial intelligence (AI) and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy when a tumor sample responds to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Through AI, it uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.

arrow icon

What is the price predicton of POAI Stock?

Wall Street analysts forecast POAI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for POAI is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Predictive Oncology Inc (POAI)'s revenue for the last quarter?

Predictive Oncology Inc revenue for the last quarter amounts to 3.62K USD, decreased -7.40 % YoY.

arrow icon

What is Predictive Oncology Inc (POAI)'s earnings per share (EPS) for the last quarter?

Predictive Oncology Inc. EPS for the last quarter amounts to -107.25 USD, increased 1377.27 % YoY.

arrow icon

What changes have occurred in the market's expectations for Predictive Oncology Inc (POAI)'s fundamentals?

The market is revising No Change the revenue expectations for Predictive Oncology Inc. (POAI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -59.64%.
arrow icon

How many employees does Predictive Oncology Inc (POAI). have?

Predictive Oncology Inc (POAI) has 23 emplpoyees as of December 05 2025.

arrow icon

What is Predictive Oncology Inc (POAI) market cap?

Today POAI has the market capitalization of 18.58M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free